Q4/07 Review Issued by Scimitar Equity Research, Inc.
BOSTON, Sept. 19 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of Neurobiological Technologies, Inc. (Nasdaq: NTIID), entitled, "The Secret of Success is Constancy of Purpose: VIPRINEX(TM) Could Restore Stroke Patients to Fuller Lives and They Will Be the Real Miracle of NTII's Achievement".
This review is available at our website: http://www.scimitarequity.com.
Neurobiological Technologies, Inc. (NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. NTIID is focused on therapies for neurological conditions that occur in connection with ischemic stroke, brain cancer, Alzheimer's disease and dementia. NTIID's strategy is to in-license and develop later-stage drug candidates that target major medical needs and that can be rapidly commercialized. NTIID's experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. For further information, please visit NTII's website at http://www.ntii.com.
NTII's common stock will trade under the symbol "NTIID" for 20 trading days to denote the recent reverse (7 for 1) split. After that time, the symbol will revert back to "NTII". Holders of record will be receiving instructions from NTII's transfer agent to define the procedures of surrendering their pre-split share certificates as well as assign their receipt of the new post-split certificates. NTIID's primary objective in authorizing the reverse split is to raise the share trading price of its common stock and to increase the number of shares of authorized but un-issued common stock.
Scimitar Equity Research, Inc. provides sponsored equity research of
the health sciences industry for the institutional and investment
|SOURCE Scimitar Equity Research, Inc.|
Copyright©2007 PR Newswire.
All rights reserved